forum.WMHelp.cz

[joniiiscosttale]

A sudden loss of vision, known as non-arteritic anterior ischemic optic neuropathy (NAION), is listed as a rare but serious side effect of Avana 100 mg, which contains avanafil as its active ingredient. NAION is a condition characterized by sudden vision loss in one or both eyes due to decreased blood flow to the optic nerve. The mechanism by which Avana 100 mg may lead to NAION is not entirely understood, but it is believed to be related to the medication's effects on blood flow. Avanafil, like other phosphodiesterase type 5 (PDE5) inhibitors, works by inhibiting the enzyme PDE5, which regulates blood flow. While the exact cause of NAION associated with PDE5 inhibitors is unclear, it is thought that the inhibition of PDE5 may lead to changes in blood flow to the optic nerve, resulting in ischemia (lack of blood flow) and subsequent vision loss. It's important to note that NAION is a rare side effect, and the overall risk of experiencing it with Avana 100mg or other PDE5 inhibitors is low. However, individuals with certain risk factors may be at a higher risk of developing NAION, including: Age over 50: NAION tends to occur more frequently in older individuals. Pre-existing eye conditions: Individuals with conditions such as diabetes, hypertension, or optic nerve abnormalities may be at increased risk. Smoking: Smoking is associated with an increased risk of NAION. Cardiovascular disease: Individuals with a history of cardiovascular disease may be at higher risk. Because of the potential risk of NAION, individuals considering the use of Avana 100 mg or other PDE5 inhibitors should discuss their medical history, including any risk factors for NAION, with their healthcare provider. Healthcare providers can help weigh the potential benefits and risks of treatment and provide guidance on appropriate use and monitoring. Additionally, individuals experiencing sudden vision loss or changes in vision while taking Avana 100 mg should seek immediate medical attention.